Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Trask

Sleep Medicine Orange, CA Medical Doctor

NPI 1346233467 CMS profile 15883

101 The City Dr S, Orange, CA 92868

Open in the dashboard

General payments

$22,752

216 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Trask of Orange, CA is reported in the CMS Open Payments database as having received $22,752 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,228 87
2024 General $3,921 73
2023 General $5,882 34
2022 General $2,981 9
2021 General $1,521 4
2020 General $944 5
2019 General $276 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Trask
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Douglas Trask were reported at $7,228. Among 41 Sleep Medicine profiles paid that year, the median was $509 and the middle half received between $149 and $1,143.

Show as a table
Year Douglas Trask Sleep Medicine median Middle half National median
2019 $276 $276 $99–$1,051 $163
2020 $944 $154 $53–$837 $114
2021 $1,521 $311 $144–$1,090 $132
2022 $2,981 $312 $80–$539 $149
2023 $5,882 $439 $154–$773 $160
2024 $3,921 $450 $149–$1,411 $164
2025 $7,228 $509 $149–$1,143 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inspire Medical Systems, Inc. $19,024 172 payments
  2. Aerin Medical Inc. $3,277 30 payments
  3. Medtronic, Inc. $132 5 payments
  4. Acell, Inc. $130 2 payments
  5. Merck Sharp & Dohme Corporation $88 1 payment
  6. Intersect ENT, Inc. $44 2 payments
  7. Smith+Nephew, Inc. $42 3 payments
  8. E.R. Squibb & Sons, L.L.C. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,175 195 payments
  2. Consulting Fee $7,613 3 payments
  3. Travel and Lodging $3,964 18 payments
Products named General payments · program years 2019–2025
  1. INSPIRE $14,360 167 payments
  2. Inspire Upper Airway Stimulation System $4,664 5 payments
  3. VIVAER STYLUS $2,825 23 payments
  4. RHINAER STYLUS $1,371 10 payments
  5. PROPEL Otolaryngology (Ear, Nose, Throat) $62 3 payments
  6. RhinAer $53 2 payments
  7. VivAer $53 2 payments
  8. StealthStation $48 1 payment
  9. PROPEL Otolaryngology (Ear, Nose, Throat) $44 2 payments
  10. SINUVA $22 1 payment
  11. Other $31 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

524

Median for Otolaryngology: 297

Drug cost

$10,445

Median for Otolaryngology: $6,314

Branded share of claims

2.3%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 175 $5,146
Ipratropium Bromide Generic 51 $1,923
Fluticasone Propionate Generic 77 $1,202
Gabapentin Generic 69 $745
Fluocinolone Acetonide Generic 16 $458
Clonazepam Generic 16 $345
Famotidine Generic 68 $327
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 12 $117
Doxycycline Monohydrate Generic 11 $85
Omeprazole Generic 14 $68

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$130,064

Medicare's payments for the services billed

Medicare patients

382

Average age 73

Services billed

1,062

174 women, 208 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 59%
Diabetes 33%
Ischemic heart disease 32%
Depression 28%
Chronic kidney disease 22%
Osteoporosis 22%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record